D-Index & Metrics Best Publications

Jane F. Apperley

Imperial College London
United Kingdom

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 109 Citations 47,385 569 World Ranking 3372 National Ranking 347

Best female scientists D-index 109 Citations 47,393 572 World Ranking 578 National Ranking 57

Research.com Recognitions

Awards & Achievements

2023 - Research.com Best Female Scientist Award

2022 - Research.com Best Female Scientist Award

Overview

What is she best known for?

The fields of study Jane F. Apperley is best known for:

Cancer
Immune system
Gene

Jane F. Apperley combines topics linked to Cohort with her work on Internal medicine. In her articles, she combines various disciplines, including Immunology and Cell biology. By researching both Cell biology and Immunology, she produces research that crosses academic boundaries. Jane F. Apperley performs multidisciplinary study in the fields of Oncology and Gastroenterology via her papers. Jane F. Apperley integrates many fields in her works, including Gastroenterology and Internal medicine. Jane F. Apperley frequently studies issues relating to Surgery and Transplantation. Her Surgery study frequently draws connections to other fields, such as Transplantation. She conducts interdisciplinary study in the fields of Genetics and Gene through her works. She performs integrative Gene and Genetics research in her work.

Her most cited work include:

Defining the Intensity of Conditioning Regimens: Working Definitions (1264 citations)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet (1171 citations)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet (1170 citations)

What are the main themes of her work throughout her whole career to date

Her research on Internal medicine often connects related areas such as Disease. Her research brings together the fields of Internal medicine and Disease. Jane F. Apperley integrates several fields in her works, including Oncology and Gastroenterology. She integrates several fields in her works, including Gastroenterology and Oncology. Her study deals with a combination of Genetics and Cancer research. Her Cancer research study frequently draws connections to adjacent fields such as Imatinib. Jane F. Apperley combines Imatinib and Nilotinib in her research. As part of her studies on Nilotinib, she often connects relevant areas like Myeloid leukemia. Her research ties Imatinib mesylate and Myeloid leukemia together.

Jane F. Apperley most often published in these fields:

Internal medicine (88.89%)
Oncology (52.22%)
Genetics (50.00%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Joan BladÉ;Diana Samson;Donna Reece;Jane Apperley.
British Journal of Haematology (1998)

2353 Citations

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Blood (2013)

2302 Citations

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus.
Blood (2006)

1772 Citations

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser.
Journal of Clinical Oncology (2009)

1754 Citations

Defining the intensity of conditioning regimens: working definitions.

Andrea Bacigalupo;Karen Ballen;Doug Rizzo;Sergio Giralt.
Biology of Blood and Marrow Transplantation (2009)

1490 Citations

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre.
The New England Journal of Medicine (2013)

1074 Citations

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

David Marin;Alexandra Bazeos;Francois Xavier Mahon;Lina Eliasson.
Journal of Clinical Oncology (2010)

1024 Citations

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation

A. Gratwohl;J. Hermans;J. Goldman;W. Arcese.
The Lancet (1998)

852 Citations

Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia

Jane F Apperley.
Lancet Oncology (2007)

811 Citations

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton.
Blood (2007)

804 Citations

If you think any of the details on this page are incorrect, let us know.